News

29 November, 2022
Edvince initiates the third cohort in phase I/II clinical trial with EDV2209 in subarachnoid haemorrhage (SAH)
30 October, 2022
Edvince completes the second cohort in phase I/II clinical trial with EDV2209 in subarachnoid haemorrhage (SAH)
31 May, 2022
Edvince completes the first cohort in phase I/II clinical trial with EDV2209 in subarachnoid haemorrhage (SAH)
14 March, 2022
Edvince recruites the first patient in phase I/II clinical trial with EDV2209 in subarachnoid haemorrhage (SAH)
15 December, 2021
Edvince selected for 2.5 mio EUR grant from the European Innovation Council Accelerator programme
7 December, 2021
Edvince receives approval from the Ethics Committee on Clinical Application for EDV2209 in subarachnoid haemorrhage (SAH)
8 September, 2021
Edvince receives regulatory approval for phase I/II in subarachnoid haemorrhage (SAH) patients